Flerie AB

Net Asset Value • Feb 5, 2025

NET ASSET VALUE – 31 January 2025

On the 31 January 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,211 million and NAV per share was SEK 53.94.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development
Prokarium	42%	482	6.18	11.5%
Xspray Pharma	18%	225	2.89	5.4%
KAHR Medical	31%	208	2.67	5.0%
Empros Pharma	79%	204	2.62	4.9%
Atrogi	37%	176	2.25	4.2%
Lipum	57%	166	2.13	3.9%
Xintela	61%	163	2.09	3.9%
Microbiotica	10%	137	1.76	3.3%
Geneos Therapeutics	12%	106	1.36	2.5%
Toleranzia	66%	105	1.35	2.5%
Mendus	24%	86	1.10	2.0%
AnaCardio	17%	69	0.89	1.6%
EpiEndo Pharmaceuticals	9%	57	0.73	1.4%
Vitara Biomedical	10%	55	0.71	1.3%
Synerkine Pharma	43%	53	0.68	1.3%
Egetis Therapeutics	2%	36	0.46	0.9%
Buzzard Pharmaceuticals	14%	29	0.37	0.7%
Sixera Pharma	24%	27	0.35	0.6%
Alder Therapeutics	21%	17	0.22	0.4%
Amarna Therapeutics	58%	12	0.15	0.3%
Strike Pharma	16%	9	0.11	0.2%
Total		2,423	31.04	57.5%
Commercial Growth
NorthX Biologics	92%	189	2.42	4.5%
Symcel	31%	174	2.23	4.1%
Nanologica	43%	82	1.05	1.9%
Provell Pharmaceuticals*	72%	81	1.04	1.9%
Chromafora	31%	73	0.93	1.7%
A3P Biomedical	8%	46	0.59	1.1%
Frontier Biosolutions	2%	19	0.24	0.5%
Bohus Biotech	45%	17	0.21	0.4%
Total		680	8.71	16.2%
Limited Partnerships, total		97	1,24	2,3%
Assets related to Portfolio companies		217	2.77	5.1%

Other assets and liabilities	794	10.17	18.9%
Net asset value	4,211	53.94	100.0%

* indirect shares in Provell Pharmaceuticals

For more information:

Ted Fjällman, CEO Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

NET ASSET VALUE – 31 January 2025